Immunoglobulin E: Role in asthma and allergic disease: Lessons from the clinic

Pharmacology and Therapeutics

Volumn 113, Issue 1, 2007, Pages 121-133

  Owen, Charles E ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Allergy; Anti IgE; Asthma; Atopy; Immunoglobulin E; Omalizumab

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E RECEPTOR; IMMUNOMODULATING AGENT; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; LUMILIXIMAB; OMALIZUMAB; PLACEBO;

ADD ON THERAPY; ALLERGIC DISEASE; ALLERGIC RHINITIS; ANTIGEN PRESENTING CELL; ASTHMA; B LYMPHOCYTE; BASOPHIL; CLINICAL TRIAL; DISEASE CONTROL; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; HAY FEVER; HUMAN; IMMUNOCOMPETENT CELL; LOADING DRUG DOSE; LOW DRUG DOSE; MACROPHAGE; MAST CELL; NONHUMAN; PEANUT ALLERGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; TH2 CELL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; RECEPTORS, IGE; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 33845808267     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2006.07.003     Document Type: Review

References (93)

1. Adelroth E., Raks S., and Haahtela T. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106 (2000) 253-259
2. Borish L., Williams J., Johnson S., Mascali J.J., Miller R., and Rosenwasser L.J. Anti-inflammatory effects of nedocromil sodium: inhibition of alveolar macrophage function. Clin Exp Allergy 22 (1992) 984-990
3. Borkowski T.A., Jouvin M.-H., Lin S.-Y., and Kinet J.-P. Minimal requirements for IgE-mediated regulation of surface FceRI. J Immunol 167 (2001) 1290-1296
4. Bos J.D., Van Leent E.J., and Sillevis S.J. The millennium criteria for the diagnosis of atopic dermatitis. Exp Dermatol 7 (1998) 132-138
5. Boulet L.P., Chapman K.R., Cote J., Kalra S., Bhagat R., Swystun V.A., et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155 (1997) 1835-1840
6. Buhl R., Kunkel G., Solèr M., Bensch G., Wolfe J., Noga O., et al. rhuMAb-25 improves asthma-specific quality of life in patients with allergic asthma. (abstract). Eur Respir J 16 Suppl. 31 (2000) 465s
7. Burrows B., Martinez F.D., Halonen M., Barbee R.A., and Cline M.G. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 320 (1989) 271-277
8. Busse W., Corren J., Lanier B.Q., McAlary M., Fowler-Taylor A., Cioppa G.D., et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108 (2001) 184-190
9. Casale T.B., Bernstein I.L., Busse W.W., LaForce C.F., Tinkelman D.G., Stoltz R.R., et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100 (1997) 110-121
10. Casale T.B., Condemi J., and Laforce C. Effect of Omalizumab on symptoms of seasonal allergic rhinitis: a randomised controlled trial. JAMA 286 (2001) 2956-2967
11. Charles N., Monteiro R.C., and Benhamou M. p28, a novel IgE receptor associated protein, is a sensor of receptor occupation by its ligand in mast cells. J Biol Chem 279 (2004) 12312-12318
12. Chervinsky P., Casale T., Townley R., Tripathy I., Hedgecock S., Fowler-Taylor A., et al. Omalizumab, an anti-IgE antibody in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 91 (2003) 160-167
13. Delespesse G., Suter U., Mossalayi D., Bettler B., Sarfati M., and Hofstetter H. Expression, structure and function of the CD23 antigen. Adv Immunol 149 (1991) 149-191
14. Dykewicz M.S., and Fineman S. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. Ann Allergy Asthma Immunol 81 (1998) 478-518
15. Dzionek A., Fuchs A., Schmidt P., Cremer S., Zysk M., Miltenyi S., et al. BDCA-2, BDCA-3 and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 165 (2000) 6037-6046
16. Fahy J.V., Fleming H.E., Wong H.H., Liu J.T., Su J.Q., Reimann J., et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155 (1997) 1828-1834
17. Fick R.B.J., Fox J.A., and Jardieu P.M. Immunotherapy approach to allergic disease. Immunopharmacology 48 (2000) 307-310
18. Foster B., Metcalfe D.D., and Prussin C. Human dendritic cell 1 and dendritic cell 2 subsets express FceRI: correlation with serum IgE and allergic asthma. J Allergy Clin Immunol 112 (2003) 1132-1138
19. Fox J.A., Hotaling T.E., Struble C., Ruppel J., Bates D.J., and Schoenhoff M.B. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 279 (1996) 1000-1008
20. Gould H.J., Sutton B.J., Beavil A.J., and Beavil R.L. The biology of IgE and the basis of allergic disease. Annu Rev Immunol 21 (2003) 579-628
21. Gounni A.S., Lamkhioued B., Ochiai K., Tanaka Y., Delaporte E., Capron A., et al. High-affinity IgE receptor on eosinophils is involved in defence against parasites. Nature 367 (1994) 183-186
22. Haczku A., Takeda K., Hamelmann E., Oshiba A., Loader J., Joetham A., et al. CD23 deficient mice develop allergic airway hyperresponsiveness following sensitization with ovalbumin. Am J Respir Crit Care Med 156 (1997) 1945-1955
23. Haczku A., Takeda K., Hamelmann E., Loader J., Joetham A., Redai I., et al. CD23 exhibits negative regulatory effects on allergic sensitization and airway hyperresponsiveness. Am J Respir Crit Care Med 161 (2000) 952-960
24. Hakonarson H., Carter C., Kim C., and Grunstein M.M. Altered expression and action of the low-affinity IgE receptor Fc epsilon RII (CD23) in asthmatic airway smooth muscle. J Allergy Clin Immunol 104 (1999) 575-584
25. Hart P.H. Regulation of the inflammatory response in asthma by mast cell products. Immunol Cell Biol 79 (2001) 149-153
26. Holgate S.T. The role of mast cells and basophils in inflammation. Clin Exp Allergy 30 (2000) 28-32
27. Holgate S., Bousquet J., Wenzel S., Fox H., Liu J., and Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr Med Res Opin 17 (2001) 233-240
28. Holgate S., Chuchalin A., Hebert J., Persson G., Chung K.F., Bousquet J., et al., and the 011 Asthma Study Group. Omalizumab improves asthma-specific quality of life in patients with severe allergic asthma. (abstract). Am J Respir Crit Care Med 163 (2001) A858
29. Holgate S.T., Chuchalin A., Hebert J., Lotvall J., Chung K.F., Bousquet J., et al. Omalizumab (Xolair®, rhumab-E25), a novel therapy for severe allergic asthma. (abstract). Am J Respir Crit Care Med 163 (2001) A812
30. Holgate S.T., Chuchalin A.G., Hebert J., Lotvall J., Persson G.B., Chung K.F., et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 34 (2004) 632-638
31. Holt P.G., and Upham J.W. The role of dendritic cells in asthma. Curr Opin Allergy Clin Immunol 4 (2004) 39-44
32. Howarth P.H., Durham S.R., Kay A.B., and Holgate S.T. The relationship between mast cell-mediator release and bronchial reactivity in allergic asthma. J Allergy Clin Immunol 80 (1987) 703-711
33. Humbert M., Durham S.R., Ying S., Kimmitt P., Barkans J., Assoufi B., et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 154 (1996) 1497-1504
34. Humbert M., Durham S.R., Kimmitt P., Powell N., Assoufi B., Pfister R., et al. Elevated expression of messenger ribonucleic acid encoding IL-13 in the bronchial mucosa of atopic and nonatopic subjects with asthma. J Allergy Clin Immunol 99 (1997) 657-665
35. Humbert M., Grant J.A., Taborda-Barata L., Durham S.R., Pfister R., Menz G., et al. High affinity IgE receptor (Fc epsilon RI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med 153 (1997) 1931-1937
36. Humbert M., Beasley R., Ayres J., Slavin R., Hebert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60 (2004) 309-316
37. Ishizaka K., and Ishizaka T. Physicochemical properties of reaginic antibody. Association of reaginic activity with an immunoglobulin other than γA- or γG-globulin. J Allergy 37 (1966) 169-185
38. Jensen B.M., Hansen J.B., and Dissing S. Monomeric immunoglobulin E stabilises FcεRIα turnover from the human basophilic cell line KU812 by protecting it from natural turnover. Clin Exp Allergy 33 (2003) 655-662
39. Johansson S.G., and Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology 13 (1967) 381-394
40. Juniper E.F., Guyatt G.H., Epstein R.S., Ferrie P.J., Jaeschke R., and Hiller T.K. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 47 (1992) 76-83
41. Juniper E.F., Guyatt G.H., Willan A., and Griffith L.E. Determining a minimal important change in the disease-specific quality of life questionnaire. J Clin Epidemiol 47 (1994) 81-87
42. Kay A.B., Barata L., Meng Q., Durham S.R., and Ying S. Eosinophils and eosinophil-associated cytokines in allergic inflammation. Int Arch Allergy Immunol 113 (1997) 196-199
43. Kehry M.R., and Yamashita L.C. Low-affinity IgE receptor (CD23) function on mouse B cells: role in IgE-dependent antigen focusing. Proc Natl Acad Sci U S A 86 (1989) 7556-7560
44. Kinet J.-P. The high affinity IgE receptor (FceRI): from physiology to pathology. Annu Rev Immunol 17 (1999) 931-972
45. King C.L., Poindexter R.W., and Ragunathan J. Frequency analysis of IgE-secreting B lymphocytes in persons with normal or elevated serum IgE levels. J Immunol 146 (1991) 1478-1483
46. Kishiyama J.L., Lanier B.Q., Corren J., Everhard F., Watrous M., Fick R., et al. rhuMAb-25 (E25) improves asthma-specific quality of life in patients with allergic asthma. (abstract). Allergy Clin Immunol Int Suppl 2 (2000) 115
47. Kisselgof A.B., and Oettgen H. The expression of murine B cell CD23, in vivo, is regulated by its ligand IgE. Int Immunol 10 (1998) 1377-1384
48. Kobayashi Y., Kondo N., Shinoda S., Agata H., Fukutomi O., and Orii T. Predictive values of cord blood IgE and cord blood lymphocyte responses to food antigens in allergic disorders during infancy. J Allergy Clin Immunol 94 (1994) 907-916
49. Kopp M.V., Brauburger J., Reidinger F., Beischer D., Ihorst G., Kamin W., et al. The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis. J Allergy Clin Immunol 110 (2002) 728-735
50. Kuehr J., Brauburger J., and Zielen S. Efficacy of a combination treatment with anti-IgE plus specific immunotherapy in polysensitised children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109 (2002) 274-280
51. Lambrecht B.N., and Hammad H. Taking our breath away: dendritic cells in the pathogenesis of asthma. Nat Rev Immunol 3 (2003) 994-1003
52. Letourneur O., Secchi S., Willette-Brown J., Robertson M.W., and Kinet J.-P. Glycosylation of human truncated FcεRIα chain is necessary for efficient folding in the endoplasmic reticulum. J Biol Chem 270 (1995) 8249-8256
53. Leung D.Y.M., Sampson H.A., Yunginger J.W., Burks Jr. A.W., Schneider L.C., Wortel C.H., et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 348 (2003) 986-993
54. Leynadier F., Doudou O., Gaouar H., Le Gros V., Bourdeix I., Guymarch-Cocco L., et al. Effect of Omalizumab in health care worker with occupational latex allergy. J Allergy Clin Immunol 113 (2003) 360-361
55. Lin S., Cicala C., Scharenberg A.-M., and Kinet J.-P. The FcεRIβ subunit functions as an amplifier of FcεRIγ mediated cell activation signals. Cell 85 (1996) 985-995
56. Lin H., Boesel K.M., Griffith D.T., Prussin C., Foster B., Romero F.A., et al. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol 113 (2004) 297-302
57. MacGlashan D.J., and Schroeder J.T. Functional consequences of Fc epsilon RIalpha up-regulation by IgE in human basophils. J Leukoc Biol 68 (2000) 479-486
58. MacGlashan D.J., McKenzie-White J., Chichester K., Bochner B.S., Davis F.M., Schroeder J.T., et al. In vitro regulation of Fc epsilon RIalpha expression on human basophils by IgE antibody. Blood 91 (1998) 1633-1643
59. MacGlashan D.J., Lichtenstein L.M., McKenzie-White J., Chichester K., Henry A.J., Sutton B.J., et al. Upregulation of Fc epsilon RI on human basophils by IgE antibody is mediated by interaction of IgE with Fc epsilon RI. J Allergy Clin Immunol 104 (1999) 492-498
60. MacGlashan D., Xia H.-Z., Schwartz L.B., and Gong J. IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcεRI in human basophils. J Leukoc Biol 70 (2001) 207-218
61. Maurer D., Ebner C., Reininger B., Fiebiger E., Kraft D., Kinet J.P., et al. The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol 154 (1995) 6285-6290
62. Maurer D., Fiebiger E., Reininger B., Ebner C., Petzelbauer P., Shi G.P., et al. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation. J Immunol 161 (1998) 2731-2739
63. Milgrom H., Fick R.B.J., Su J.Q., Reimann J.D., Bush R.K., Watrous M.L., et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. N Engl J Med 341 (1999) 1966-1973
64. Milgrom H., Berger W., Nayak A., Gupta N., Pollard S., McAlary M., et al. Treatment of childhood asthma with anti-immunoglobulin e antibody (omalizumab). Pediatrics 108 (2001) E36
65. National Asthma Education and Prevention Program Expert Panel. Expert Panel No. 2: Guidelines for the Diagnosis and Management of Asthma. NIH Publication Vol. 97-4051 (1997), National Heart, Lung, and Blood Institute, Bethesda, MD
66. Novak N., and Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 112 (2003) 252-262
67. Novak N., Tepel C., Koch S., Brix K., Bieber T., and Kraft S. Evidence for a differential expression of the FcεRIγ chain in dendritic cells of atopic and nonatopic donors. J Clin Invest 111 (2003) 1047-1056
68. Novak N., Bieber T., and Leung D.Y.M. Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 112 (2003) 128-129
69. Oettgen H.C., and Geha R.S. IgE in asthma and atopy: cellular and molecular connections. J Clin Invest 104 (1999) 829-835
70. Platts-Mills T.A.E. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 164 (2001) S1-S5
71. Plewako H., Arvidsson M., Petruson K., Oancea I., Holmberg K., Adelroth E., et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 110 (2002) 68-71
72. Presta L.G., Lahr S.J., Shields R.L., Porter J.P., Gorman C.M., Fendly B.M., et al. Humanization of an antibody directed against IgE. J Immunol 151 (1993) 2623-2632
73. Presta L., Shields R., O'Connell L., Lahr S., Porter J., Gorman C., et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 269 (1994) 26368-26373
74. Prussin C., Griffith D.T., Boesel K.M., Lin H., Foster B., and Casale T.B. Omalizumab treatment downregulates dendritic cell FcεRI expression. J Allergy Clin Immunol 112 (2004) 1147-1157
75. Rackeman F.M. A working classification of asthma. Am J Med 33 (1947) 601-606
76. Riffo-Vasquez Y., Spina D., Thomas M., Gilbey T., Kemeny D.M., and Page C.P. The role of CD23 on allergen-induced IgE levels, pulmonary eosinophilia and bronchial hyperresponsiveness in mice. Clin Exp Allergy 30 (2000) 728-738
77. Rosenwasser L.J., Busse W.W., Lizambri R.G., Olejnik T.A., and Totoritis M.C. Allergic asthma and an anti-CD23 mAb (IDEC-152): results of a phase I, single dose, dose-escalating clinical trial. J Allergy Clin Immunol 112 (2003) 563-570
78. Saini S.S., Macglashan D.W.J., Sterbinsky S.A., Togias A., Adelman D.C., Lichtenstein L.M., et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 162 (1999) 5624-5630
79. Sampson H.A. Food allergy. Part 1: immunopathogenesis and clinical disorders. J Allergy Clin Immunol 103 (1999) 717-728
80. Semper A.E., Heron K., Woollard A.C.S., Kochan J.P., Friedmann P.S., Church M.K., et al. Surface expression of FcεRI on Langerhan's cells of clinically uninvolved skin is associated with disease activity in atopic dermatitis, allergic asthma and rhinitis. J Allergy Clin Immunol 112 (2003) 411-419
81. Sicherer S.H., Munoz-Furlong A., Burks A.W., and Sampson H.A. Prevalence of peanut and tree nut allergy in the US determined by a random digit telephone survey. J Allergy Clin Immunol 103 (1999) 559-562
82. Smurthwaite L., and Durham S.R. Local IgE production in allergic rhinitis and asthma. Curr Allergy Asthma Rep 2 (2002) 231-238
83. Smurthwaite L., Walker S.N., Wilson D.R., Birch D.S., Merrett T.G., Durham S.R., et al. Persistent IgE synthesis in the nasal mucosa of hay fever patients. Eur J Immunol 31 (2001) 3422-3431
84. Sole D., Yamada E., Vana A.T., Werneck G., Solano D.F., Sologuren M.J., et al. International Study of Asthma and Allergies in Childhood (ISAAC): prevalence of asthma and asthma-related symptoms among Brazilian schoolchildren. J Investig Allergol Clin Immunol 11 (2001) 123-128
85. Solèr M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 18 (2001) 254-261
86. Tada T., Okumura K., Platteau B., Beckers A., and Bazin H. Half-lives of two types of rat homocytotropic antibodies in circulation and in the skin. Int Arch Allergy Appl Immunol 48 (1975) 116-131
87. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema. Lancet 351 (1998) 1225-1232
88. Umetsu D.T., and DeKruyff R.H. Th1 and Th2 CD4+ cells in the pathogenesis of allergic diseases. Proc Soc Exp Biol Med 215 (1997) 11-20
89. van der Heijden F.L., Joost V.N.R., van Katwijk M., Bos J.D., and Kapsenberg M.L. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol 150 (1993) 3643-3650
90. Vignola M., Bousquet J., Maspero J., Fox H., Hedgecock S., and Blogg M. Treatment of co-morbid allergic asthma and perennial allergic rhinitis with the anti-IgE agent omalizumab. Eur Respir J 22 Suppl. 45 (2003) S203
91. Wilson D.R., Merrett T.G., Varga E.M., Smurthwaite L., Gould H.J., Kemp M., et al. Increases in allergen-specific IgE in BAL after segmental allergen challenge in atopic asthmatics. Am J Respir Crit Care Med 165 (2002) 22-26
92. Ying S., Humbert M., Meng Q., Pfister R., Menz G., Gould H.J., et al. Local expression of ε germline gene transcripts and RNA for the ε heavy chain of IgE in the bronchial mucosa in atopic and nonatopic asthma. J Allergy Clin Immunol 107 (2001) 686-692
93. Yu P., Kosco-Vilbois M., Richards M., Kohler G., and Lamers M.C. Negative feedback regulation of IgE synthesis by murine CD23. Nature 369 (1994) 753-756